Form 4: Foghorn Therapeutics Director Thomas J. Lynch Jr. Acquires Stock Options

Director Thomas J. Lynch Jr. of Foghorn Therapeutics Inc. (FHTX) acquired 16,000 stock options on June 26, 2024, at a price of $5.52 per option.

Summary

• On June 26, 2024, Thomas J. Lynch Jr., a director of Foghorn Therapeutics Inc. (FHTX), acquired 16,000 stock options.
• The options were acquired at a price of $5.52 each.
• The options become exercisable on June 26, 2025, and expire on June 25, 2034.
• This transaction was reported on a Form 4 filed with the SEC on June 28, 2024.
• Lynch has granted a Limited Power of Attorney to Kristian Humer, Michael LaCascia and Tara Maduri to handle SEC filings related to his holdings in Foghorn Therapeutics.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral. It reflects standard insider activity.

Positives

• The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who have transactions in their company's securities. It provides transparency to the market regarding insider activity.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies.
• The reporting of these transactions is mandated by the SEC to ensure transparency and prevent insider trading.
• Comparable companies in the biotechnology sector also have similar insider transaction reporting requirements.

Stakeholder Impact

• The transaction provides information to shareholders about insider activity, which can influence investor sentiment.

Key Dates